Fig. 1 (abstract O1).From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstractsClinical outcomes in CD8+/PD-L1+ or PD-L1 NSCLC patient subsetsBack to article page